Oncology

Clinical trials for Oncology specialty

  • Description

    Weight loss is one of the few factors that have consistently been shown to be associated with shortened survival in people with lymphoma. This study aims to document how often dogs experience weight loss or decrease in muscle mass at the time that lymphoma is diagnosed, and whether this finding impacts how dogs respond to treatment.

    Inclusion Criteria

    Dogs with multicentric lymphoma that have undergone full staging.

    Exclusion Criteria

    Prior chemotherapy (including prednisone) or dogs with lymphoma within the gastrointestinal tract.

    Client Benefits

    None

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682

  • Description

    The Cummings School of Veterinary Medicine at Tufts University was selected as a contributing site for theCCOGC Biospecimen Repository. This is an innovative multi-institutional endeavor organized by researchers at the NCI to create a large tissue repository of spontaneous canine cancers.

    The tissues within these repositories will be used for future investigations by researchers at locations across the country to allow a better understanding of canine and human cancers.

    Inclusion Criteria

    Any dog that will be undergoing a surgical procedure as part of his/her treatment. At the time of surgery, the tumor is sent to the pathology laboratory for diagnosis or examination. When these tests are completed, the remainder of the tissue is usually discarded. We would like to acquire any left over tissue to use for archiving purposes.

    Exclusion Criteria

    None.

    Client Benefits

    There is no direct benefit for participating in the tissue collection and banking. However your participation may help in understanding the genetic basis for canine (and possibly human) cancers.

    Contact Information

    Kristin Marshall, Oncology Clinical Trials Coordinator
    Phone: (508) 887-4422

  • Description

    Prior studies in the human and veterinary literature suggest that the use of a bisphosphate in the treatment of canine osteosarcoma may be effective in extending overall survival.

    The goal of this study is to evaluate the tolerability and efficacy of a bisphosphate, pamidronate, given in conjunction with standard of care chemotherapy for dogs with appendicular osteosaroma post amputation.

    Inclusion Criteria

    Dogs with osteosarcoma that have undergone surgery for removal of the affected limb.

    Exclusion Criteria

    Dogs must have no pre-existing renal disease.

    Client Benefits

    This study is not funded; so pet owners are responsible for all costs associated with this treatment.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682

  • Description

    Although canine lymphoma is highly responsive to chemotherapy, the disease is rarely cured since the disease recurs in most dogs that receive chemotherapy. The goal of this study is to determine the highest dose of cyclophosphamide that can be given safely with cytokine support and whether this treatment will prolong remission duration beyond standard chemotherapy protocols.

    Inclusion Criteria

    Dogs with multicentric lymphoma in complete remission after multiagent CHOP-based induction chemotherapy.

    Exclusion Criteria

    Dogs with other significant medical conditions or who lower urinary tract disease are ineligible to participate in this study.

    Client Benefits

    Dog owners are financially responsible for costs associated with standard chemotherapy. Additionally the owner may be financially responsible for all tests that determine if the patient qualifies for the study. These tests may include re-check examination fees, blood and urine tests.

    This study covers the cost associated with high-dose cyclophosphamide treatment, monitoring and supportive care.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682

  • Description

    The main goals of this study are to correlate the different histologic subtypes of canine lymphoma with gene expression and response to treatment and survival time.

    Inclusion Criteria

    All dogs with newly diagnosed multicentric lymphoma that have enlarged peripheral lymph nodes are eligible for entry into this study.

    Exclusion Criteria

    Patients that have received prior chemotherapy are not eligible for participation in this study.

    Client Benefits

    The owner is financially responsible for all tests that determine if the patient qualifies for the study. These tests may include initial specialty examination, blood and urine tests.

    The study will cover the costs of blood collection and histopathologic evaluation, including immunophenotype of your dog’s lymph node tissue (if applicable).

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682

  • Description

    Osteosarcoma is the most common primary bone tumor in dogs. Despite aggressive treatment with surgery and chemotherapy, most dogs die of metastatic disease that is resistant to conventional chemotherapy. Metronomic chemotherapy entails very small doses of chemotherapy that are given daily or every other day and help to deter the growth of new blood vessels needed to nourish cancer as it grows. Side effects associated with metronomic chemotherapy tend to be milder and less frequent than those seen with standard chemotherapy. The goal of this study is to evaluate for an increased disease free interval in dogs treated with standard of care surgery and chemotherapy followed with maintenance metronomic or low dose chemotherapy.

    Inclusion Criteria

    Dogs with osteosarcoma that have completed a standard course of chemotherapy after limb amputation.

    Exclusion Criteria

    Dogs with a life expectancy of less than 1 month or who have lower urinary tract disease are ineligible to participate in this study.

    Client Benefits

    This study is not funded; so pet owners are responsible for all costs associated with this treatment.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682

  • Description

    The goal of this study is to evaluate the efficacy of low dose of metronomic chemotherapy as a maintenance therapy in dogs with hemangiosarcoma.

    Hemangiosarcoma is a common tumor developing in the spleen of dogs. Despite aggressive treatment with surgery and chemotherapy, most dogs die of metastatic disease shortly after treatment.

    Metronomic or LDC entails very small doses of chemotherapy that are given daily or every other day and help to deter the growth of new blood vessels needed to nourish cancer as it grows. Side effects associated with metronomic chemotherapy tend to be milder and less frequent than those seen with standard chemotherapy.

    This form of chemotherapy has been used in dogs with spenic hemangiosarcoma after surgery and has been found to have efficacy as a single agent.

    Inclusion Criteria

    Dogs with hemangiosarcoma that have completed a standard course of chemotherapy after removal of the affected spleen.

    Exclusion Criteria

    Dogs with a life expectancy of less than 1 month or who have lower urinary tract disease are ineligible to participate in this study.

    Client Benefits

    This study is not funded; so pet owners are responsible for all costs associated with this treatment.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682

  • Description

    This preclinical trial, sponsored by the National Cancer Institute, is designed to evaluate three new chemotherapy agents in the indenoisoquinoline class. These drugs inhibit topoisomerase I, which is an enzyme important in DNA replication, and have shown efficacy in a variety of cancers.
    The intent of this study is to define and compare the pharmacologic effects of these three drugs in dogs with lymphoma. Specifically, the study will assess basic properties of the drug, such as duration of action, markers of damage to DNA in cancer cells, and safety. The goal is to determine the appropriate dose of each drug and to determine if there are differences in biologic activity among the drugs. The response to treatment, specifically whether lymphoma goes into remission in the treated dogs, will also be assessed.

    Inclusion Criteria

    • Dogs of any age
    • Cytologically or histologically confirmed diagnosis of lymphoma involving multiple external lymph nodes
    • Dogs must be feeling well or only minimally compromised
    • Dogs either must not have received treatment for lymphoma for at least 2 weeks prior to enrollment in the study

    Exclusion Criteria

    • Significant illness (such as kidney failure, liver disease, heart failure, severe anemia)
    • Dogs weighing less than 33 pounds
    • Dogs who have received prednisone for any reason in the two weeks prior to study enrollment

    Client Benefits

    This study is fully funded and will cover the cost of treatment, monitoring tests and management of treatment related side effects. Dogs that complete the 28-day study will be eligible to receive $1000 for further medical care at Tufts.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682
    Email: Veterinaryoncology@tufts.edu

  • Description

    The goal of this study is to evaluate a novel chemotherapy agent, GS-9219, for efficacy and toxicity in a population of dogs with a confirmed diagnosis of T cell cutaneous lymphoma. Canine cutaneous lymphoma is an uncommon but uniformly fatal canine disease. While most dogs may respond to treatment with chemotherapy, responses can be variable and are generally short in duration. New treatments for this disease are needed to improve patient comfort and survival.

    Clients will be responsible for the cost of diagnosis and staging to determine eligibility prior to enrollment (~$350). You are also responsible for the cost of the recheck examination at each visit ($50), the cost of prednisone and any other ancillary medications during the study, as well as any other tests recommended by your pet’s oncologist. You are expected to make and keep all appointments, according to the clinical trial protocol once enrolled.

    Inclusion Criteria

    Dogs with biopsy confirmed cutaneous T cell lymphoma are eligible to participate. Dogs should be otherwise in good health and must have adequate organ function as determined by blood work and urinalysis. Previous treatment is allowable provided dogs have not received any chemotherapy in the past 3 weeks, radiation therapy in the past 6 weeks, or retinoid therapy in the past 7 days. West Highland White Terriers are not eligible to participate in this study because of the breed’s genetic predisposition toward idiopathic pulmonary fibrosis.

    Exclusion Criteria

    Client Benefits

    Clients participating in this study will be given special financial considerations. Specifically, all costs of blood work, urinalysis(s), x-rays and biopsies performed during the study are covered, as well all costs associated with administration of GS-9219. Additionally, a $500 credit will be applied to the pet’s account at the Foster Hospital for Small Animals at Tufts University at the completion of the study.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682
    Email: Veterinaryoncology@tufts.edu

  • Description

    Transitional cell carcinoma (TCC) is one of the most common cancers of the canine urinary tract. Existing treatment options for this disease have resulted in only modest benefit. Studies in both humans and dogs suggest tyrosine kinase inhibitors can provide a benefit in controlling disease progression for various solid tumors. Toceranib phosphate (Palladia®, Pfizer) is a FDA approved multi-targeted tyrosine kinase inhibitor for dogs with mast cell tumor. The purpose of this study is to evaluate the safety and potential efficacy (tumor response) of toceranib phosphate in management of canine transitional cell carcinoma.

    Inclusion Criteria

    Dogs with TCC who have had tumor progression while receiving non-steroidal anti-inflammatory drugs (NSAID). Dogs must have a measurable tumor on abdominal ultrasounds.

    Exclusion Criteria

    Dogs with other significant medical conditions, kidney problems or GI ulcers that may limit the use of NSAIDs are ineligible from participating in this study.

    Client Benefits

    The owner is financially responsible for all tests that determine if the patient qualifies for the study. These tests may include abdominal ultrasounds, chest X-rays, blood and urine tests.

    This study covers the cost of a limited number and portion of re-check examination fees, pre-treatmentCBC/platelet counts, abdominal ultrasounds, and chemistry profiles. Toceranib phosphate will be provided to the owner at no charge.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508)887-4682

  • Description:

    Lymphoma is one of the most common cancers in the dog and is comparable to non-Hodgkin’s lymphoma in humans. Chemotherapy is the standard of care for treatment and can provide long term disease control but survival beyond 2 years is rare.

    There is active investigation into the utility of metabolic markers, such as insulin-like growth factor 1 (IGF-1), as a predictor of response to treatment in humans with non-Hodgkin’s lymphoma. Additionally these markers may serve as a target for future therapy.

    The goal of this study is to assess levels of IGF-1 and other related blood biomarkers in canine patients with lymphoma. We will evaluate these markers for prognostic value and will determine whether they could serve as targets for therapy in the future.

    Inclusion Criteria:

    Dogs with a confirmed diagnosis of multicentric lymphoma (cytology or pathology), weighing more than 25kg. Dogs must be eating a commercial diet and be otherwise healthy.

    Exclusion Criteria:

    Dogs with other systemic diseases (diabetes mellitus, hypothyroidism, Cushing’s disease, kidney disease, liver disease, etc). Dogs eating a home-cooked or raw diet.

    Client Benefits:

    No direct benefits. Dog owners are financially responsible for the costs associated with cancer staging plus standard chemotherapy and recommended treatment monitoring (weekly complete blood counts).

    This study covers the cost of measurement of IGF-1 and other metabolites.

    Contact Information:

    Kelly Reed, Oncology liaison

    508-887-4682

     

     

     

     

  • Description

    The goal of this study is to evaluate therapy with toceranib (Palladia®), an oral anticancer agent, in combination with palliative radiation therapy for tolerability, toxicity, and efficacy in a population of dogs with measurable carcinomas. Carcinomas are a common malignancy in both dogs and humans. As a category of cancer, carcinomas tend to be both locally invasive as well as carry a high risk of locoregional metastasis. While most dogs diagnosed in early stages may respond well to multimodality therapy, survival is generally thought to be shorter for bulky or metastatic tumors. New treatments for advanced carcinomas are needed to improve patient comfort and survival.

    Inclusion Criteria

    Dogs with cytologic or histology confirmation of the following carcinomas are eligible to participate in this study: anal sac adenocarcinoma, ceruminous gland carcinoma, mammary gland carcinoma, nasal carcinoma, prostatic carcinoma, salivary gland carcinoma, sebaceous adenocarcinoma, squamous cell carcinoma, rectal carcinoma, thyroid carcinoma, or transitional cell carcinoma of the urethra. The patient must have measurable disease at the primary tumor site and/or metastatic lymph nodes. Dogs should be otherwise in good health, a candidate for 10 daily anesthetic episodes, and must have adequate organ function as determined by blood work and urinalysis. Previous chemotherapy or surgery is allowable provided it is a minimum of 2 weeks prior to enrollment in the trial. Prior NSAID therapy is allowed if the patient has been on this therapy for minimum of 2 weeks prior to enrollment. Any homeopathic/alternative therapies for cancer must be discontinued prior to enrollment.

    Exclusion Criteria

    The following carcinomas are ineligible for participation: adrenocortical carcinoma, gastrointestinal carcinoma (excluding rectal), renal carcinoma, or transitional cell carcinoma of the urinary bladder. Dogs are also ineligible if they have received prior radiation therapy to the tumor site.

    Client Benefits

    Clients participating in this study will be given special financial considerations. Specifically, the study will cover the following costs associated with participation in this clinical trial: the cost of Palladia for 12 weeks, $1250 towards radiation therapy, one set of chest x-rays (at week 12), and recheck exam fees at week 3, 4, 6, and 12 of the study. This amounts to a total financial benefit of approximately $2200.

    The client will be responsible for general anesthesia and costs for the CT scan (if required); all radiation therapy costs beyond $1250; all costs associated with monitoring blood work and urinalyses during the study period and beyond; and any diagnostic tests (x-rays, abdominal ultrasound, etc.) and recheck exam fees beyond week 12. The client is expected to make and keep all appointments, according to the clinical trial protocol once enrolled.

    Contact Information

    Kelly Reed, Oncology Liaison
    Phone: (508) 887-4682